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Knowledge about evidence-based medicine selection and the role of the Drug and Therapeutics Committee 
(DTC) is an important topic in the literature but is scarcely discussed in Brazil. Our objective, using 
a qualitative design, was to analyze the medicine selection process performed in four large university 
hospitals in the state of Rio de Janeiro. Information was collected from documents, interviews with key 
informants and direct observations. Two dimensions were analyzed: the structural and organizational 
aspects of the selection process and the criteria and methods used in medicine selection. The findings 
showed that the DTC was active in two hospitals. The structure for decision-making was weak. DTC 
members had little experience in evidence-based selection, and their everyday functions did not influence 
their participation in DTC activities. The methods used to evaluate evidence were inadequate. The 
uncritical adoption of new medicines in these complex hospital facilities may be hampering pharmaceutical 
services, with consequences for the entire health system. Although the qualitative approach considerably 
limits the extent to which the results can be extrapolated, we believe that our findings may be relevant 
to other university hospitals in the country.
Uniterms: Medicines/selection. Drug and Therapeutic Committees. University hospitals/medicines 
selection.
A produção de conhecimento sobre a seleção de medicamentos baseada em evidências e executada por 
Comissões de Farmácia e Terapêutica é ainda escassa no Brasil, apesar da ampla discussão sobre o tema 
em países desenvolvidos. Este estudo buscou conhecer e analisar os aspectos relacionados à seleção 
de medicamentos em quatro hospitais universitários de grande porte no Rio de Janeiro, por meio de 
abordagem qualitativa. Entrevistas, observação direta e análise documental instrumentaram a coleta de 
dados qualitativos e quantitativos. A análise considerou duas dimensões: (i) estrutura e organização para 
o processo de seleção e (ii) critérios e métodos utilizados para avaliação. Apenas dois hospitais possuíam 
Comissão de Farmácia e Terapêutica (CFT) ativa. A estrutura para a tomada de decisão era deficiente 
e os membros das Comissões apontaram pouca experiência e disponibilidade para a atividade. Os 
métodos de avaliação e critérios observados indicaram um processo de seleção acrítico nestes hospitais, 
comprometendo a assistência farmacêutica e potencialmente prejudicando o sistema de saúde. Apesar 
da metodologia qualitativa não permitir a extrapolação de resultados, é possível que este cenário seja 
parecido com o de outros hospitais universitários brasileiros.
Unitermos: Medicamentos/seleção para uso. Comissão de Farmácia e Terapêutica. Hospitais 
universitários/seleção de medicamentos.
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INTRODUCTION
The rational use of health technologies – medicines, 
equipment and devices, medical and surgical procedures, 
organization and support systems (Brasil, 2010) – implies 
that their selection must be satisfactory to justify financing 
decisions and also requires the identification of the 
conditions in which they must be used (Krauss-Silva, 
2003). Clinical, social and economic impacts should be 
considered in terms of analyses of efficacy, safety and 
comparative cost-effectiveness. In the case of medicines, 
the World Health Organization states that activities 
linked to the selection process must be performed, either 
in institutions or in health systems, by the Drug and 
Therapeutics Committee (DTC), with the participation of 
health professionals with expertise in the assessment of 
scientific evidence (WHO, 2003).
The DTC must have clear goals, a firm mandate, 
support from institutional management or government, 
transparency in its procedures, wide representation, 
technical competence, multidisciplinary focus and 
sufficient resources to implement its decisions (WHO, 
2003).
These Committees have several functions. Their 
main roles involve the evaluation and selection of 
medicines and the development hospital wise use of 
medicines policies, including guidelines and therapeutic 
monitoring (WHO, 2003). DTC activities are well 
established in most European countries, the USA, 
Canada and Australia. In Brazil, these committees are 
non-mandatory, and their implementation has not been 
forthcoming (Marques, Zucchi, 2006; Veber et al., 2011). 
A 2003 national assessment showed that a mere 29 (11%) 
of 250 investigated hospitals presented nominal DTCs, 
but operational DTCs were seen in only 3.6% of hospitals 
(Osorio-de-Castro, Castilho, 2004).
University hospitals have a central role in highly 
complex health care. Due to this profile, they tend to adopt 
new technologies (Medici, 2001). Theoretically, they are 
an adequate setting for health technology assessment and 
DTC membership. Clinical decision makers participating 
in the education of other health professionals and other 
stakeholders involved in health innovation are present in 
this setting.
Because the adoption of new technologies has very 
important clinical and financial impact for patients, health 
institutions and systems, it is relevant to understand the 
selection process in greater depth. This process determines 
the technologies that will eventually be acquired and 
used. In terms of the adoption of new technologies, this 
generalization is especially true for tertiary Brazilian 
university hospitals, which are perceived as playing a 
leadership role in the health system and where intense 
pharmaceutical marketing practices are ongoing (Palácios, 
Rego, Lino, 2008).
The principal trend-setters are hospitals located in 
the more developed Brazilian Southeast. These services 
are viewed as a gateway for the entire health system in 
terms of the adoption of new technologies. This study aims 
to analyze the medicine selection process in four tertiary 
university hospitals in the state of Rio de Janeiro.
METHODOLOGY
A multiple case study was conducted (Yin, 2005). 
The research involved the collection and analysis of 
quantitative and qualitative data, with the objective of 
understanding the role of the DTCs (if present), the 
alternative selection process (if no DTC existed), the 
perspectives of the actors involved and other underlying 
aspects related to the selection of medicines in these 
hospitals.
Brazil  has 39 tert iary university hospitals 
characterized by (a) a highly complex care profile, (b) 
the presence of multiple medical specialties and (c) a 
clinical body composed primarily of professors (Medici, 
2001; Portela et al., 2004). Fifteen of these hospitals are 
in the Southeast. All tertiary university hospitals in the 
State of Rio de Janeiro were selected for study because 
of their geographical proximity and because of the size of 
the State´s population (16 million people) (Brasil, 2011; 
Abrahue, 2012; IBGE, 2012).
A reference matrix organized in dimensions — (i) 
structure and organization of the selection process and (ii) 
criteria and methods adopted — guided the collection, data 
analysis and presentation of results. This matrix was based 
on WHO recommendations on the evaluation and selection 
of medicines, on experiences in several countries (USA, 
Canada, United Kingdom, England, Spain, Denmark, 
Laos, Australia, Nepal, Sweden, Holland, Germany) 
reported in the scientific literature and on a national 
Brazilian gold standard institution (Lima-Dellamora et 
al., 2014).
A pilot study in a specialized 114-bed public 
teaching hospital was conducted to improve data 
collection instruments and procedures. A total of 27 visits 
were made to the selected hospitals between January and 
June, 2011. Data collection was accomplished through (i) 
document search, (ii) semi-structured interviews with key 
stakeholders and (iii) direct observation.
Information from hospital documents included 
description of the health care profile and details pertaining 
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to the medicine selection process, such as an essential 
medicines list (EML); minutes of the DTC meetings; forms 
for requesting inclusion of medicines in the EML; requests 
for purchase of non-formulary medicines; forms or other 
documents related to medicines donations or medicines 
involved in clinical research; and other documents such 
as ordinances, statutes, internal communications, reports, 
studies or drug use evaluations and hospital pharmacy 
records.
The interviews were performed with 17 key 
stakeholders involved in the medicine selection process, 
such as hospital managers (general director and/or clinical 
director), heads of hospital pharmacy services and DTC 
members. All signed an informed consent form.
Direct observation of the DTC meetings was 
important in understanding the subtleties of the 
environment and the workings of the selection process. 
All information on (a) the structure and organization used 
for selection, (b) membership and participation criteria, (c) 
roles and responsibilities, (d) criteria, and (e) methods used 
throughout the drug evaluation process was recorded in a 
field journal, facilitating comparisons with information in 
documents and interviews.
The analysis  was preceded by a  thorough 
organization of information based on dimensions 
(hereafter termed categories) in the reference framework. 
The interviews were analyzed based on content analysis, 
first by identification of a set of central nuclei (Bardin, 
2002) and subsequently organized in the pre-established 
categories and compared to the framework (Lima-
Dellamora et al., 2014).
The project was approved by the National Public 
Health School Ethics in Research Committee.
RESULTS
The four hospitals selected were coded as A, B, 
C and D to make their identification more difficult. The 
number of beds varied from 186 to 466 (Table I). All 
facilities had wards for highly complex care in Oncology, 
Nephrology, Neurology, Critical Care and Orthopedics. 
Three hospitals offered transplant services.
The ratio between the number of physicians and the 
number of beds was relatively homogeneous – between 
2 (hospital D) and 2.76 (hospital C) – whereas the total 
number of health professionals per bed varied from 3.55 
(hospital C) to 7.67 (hospital D).
The DTC was cited as responsible for the process 
of selecting medicines in hospitals A, B and C but was 
official only in A and B (Table II). In hospital C, the DTC 
activities had been suspended, as mentioned by one of the 
interviewees:
 The DTC selected [the medicines]. But this routine 
was subverted; (…) the DTC has stopped its ac-
TABLE I - Care profile of large, highly complex university hospitals. State of Rio de Janeiro, 2011
PROFILE
HOSPITALS
A B C D
Patient flow
Reference and 
Counter-reference
Spontaneous 
Demand + Reference 
and Counter-
reference
Reference and 
Counter-reference
Spontaneous 
Demand + Reference 
and Counter-
reference
Health Insurance SUS* SUS Private Insurance, SUS SUS
Beds
Surgery 114 85 175 188
Intensive Care 31 18 35 69
Other 107 83 232 209
Total 252 186 442 466
Hospital staff
Physicians 607 443 1221 940
Other Health 
Professionals 689 516 349 2636
Total 1296 959 1570 3576
Facilities (rooms and 
offices)
100 141 102 289
*SUS: Sistema Único de Saúde (Brazil’s Unified Health System). Source: Brasil, 2011.
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tivities. [As in the case of] clopidogrel: Cardiology 
requested it and Management suffered pressure to 
adopt it without any kind of evaluation (Interviewee 
13).
In Hospital D, Pharmacy Services Management was 
responsible for decisions on medicine selection.
 The Pharmacy selects the medicines. But it’s confus-
ing; [actually] there are several other ways in which 
medicines are adopted here (Interviewee 17).
Structural and organizational aspects of the 
selection process
The results are presented in Table 3 (DTC structure 
and membership) and Table 4 (DTC functions). Important 
limitations were observed regarding DTC organization 
in cases in which this committee was present. In hospital 
D, information about the organization of the selection 
process within the Hospital Pharmacy was sought but was 
nonexistent (Table III).
In hospitals A and B, DTC meetings were held in 
the Board Room, which appeared to make activities more 
difficult due to a work environment that did not meet the 
needs of the DTC:
 We lack a meeting room, equipment, a computer (...). 
So, it’s tough (Interviewee 9).
The DTCs of hospitals A and B had up-to-date 
statutes and procedures. In these same hospitals, there 
had been at least one DTC meeting within the six-month 
data collection period. Hospital management followed up 
activities. When questioned, however, managers did not 
produce even rough estimates of the yearly expenditures 
on medicines.
The DTCs of hospitals A and B had, on average, 
eight members, including doctors, nurses and pharmacists. 
Professors or department heads of Internal Medicine, 
Surgery, Oncology and Infectious Diseases (or the 
Hospital Infection Control Committee) usually represented 
the medical specialties. The Committees had no clinical 
pharmacologists.
All members, without exception, mentioned the 
inability to reconcile their work routines and DTC 
demands. The members prioritized other activities, 
indicating this as one of their main difficulties:
TABLE II - Responsibilities pertaining to medicine selection in university hospitals. State of Rio de Janeiro, 2011
ASPECTS
HOSPITALS
A B C D
Responsible entity DTC DTC DTC Pharmacy / Technical Services Coordination
Ordinance constituting 
DTC Yes Yes No No
Frequency of DTC 
meetings
Non-regular monthly 
meetings
Regular monthly 
meetings
Meetings temporarily 
suspended Meetings nonexistent
Available DTC 
documentation (year)
Pharmacy Manual 
(2010) 
Service 
Communication 
(2008, 2011) 
DTC Minutes of 
Meetings (2010-2011) 
Medicine Inclusion 
Forms (2010-2011) 
Medicine Request 
Documents (2010-
2011) 
Opinion about 
Inclusion Requests 
(2010) 
Medicine Inclusion 
Request Protocol 
(2010)
Essential Medicines 
List (2010)  
DTC Internal 
Regiment (2010) 
DTC Members 
Indication Ordinance 
(2010) 
DTC Minutes of 
Meetings (2010-2011) 
Medicines Inclusion 
Forms (2010-2011) 
Non-Standard 
Medicines Requests 
(2011) 
DTC Members 
Indication Ordinance 
(2008, 2010) 
DTC Minutes of 
Meetings (2008 
-2010) 
Medicines 
Procurement Service 
Orders (2009 -2011) 
Internal 
Communications 
about Medicines 
Procurement and 
Standardization (2009 
-2011) 
Medicines Inclusion 
Requests (2008-2009) 
DTC Bylaw (2003)
Medicines 
Procurement Requests 
(2011) 
Internal 
Communications 
about Medicines 
Procurement (2011) 
Medicines Inclusion 
Requests (2011)
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TABLE III - Structure and organization of DTCs (or other) related to medicine selections in university hospitals. State of Rio de 
Janeiro, 2011
STRUCTURE AND 
ORGANIZATION 
FOR SELECTION
HOSPITALS
A B C D*
Technical and 
administrative support 
for DTC (office space, 
human resources, access 
to databases) 
Non-exclusive 
secretary support No support No support No DTC
Documenting decisions, 
policies and guidelines 
as permanent hospital 
records
EML updated, not 
published. 
Recent documents 
filed with  
the secretary
EML updated and 
available online. 
Incomplete 
documentation filed  
with MB
No EML 
Incomplete 
documentation filed 
 in Pharmacy.
EML not published 
and not updated. 
Few documents filed 
in Pharmacy. 
Support and monitoring 
of activities by hospital 
board or medical board 
(MB) 
Direct participation 
of MB as  
DTC member.
Direct participation 
of MB as 
 DTC member.
No support Incipient support
Proposals and 
alternatives to distance 
committee members 
from potential conflicts 
of interest
None None None No DTC
Committee membership
MB (president), 
representation 
by sector: IHC, 
Cardiology, 
Hematology, 
Anesthesiology, 
Pharmacy and 
ICC according to 
ordinance. 
No definition of 
working hours or 
members´ terms.
MB, representation 
by clinic/service: 
General Surgery 
(president), Oncology, 
Hematology, 
Pharmacy and Nurse. 
No definition of 
working hours and 
members’ terms.
No assignment during 
this study. 
No definition of 
working hours or 
members’ terms.
No DTC
Participation criteria
Sector Heads 
and pharmacist 
indicated by Hospital 
Pharmacy; 
(public servants only).
Medical specialists 
and Pharmacy Head 
representation. 
(public servants only).
Medical specialists 
and Pharmacy Head 
representation. 
(interns, residents and 
public servants).
No DTC
Presence of ad hoc 
consultants
No definition 
in the bylaw.
No definition in the 
bylaw.
No definition 
in the bylaw. No DTC
MB: Medical Board, IHC: Intensive Health Care; ICC: Infection Control Committee, EML: Essential Medicines List.
 The committee demands more time than I have to 
offer. This is a constant problem for everyone. We 
meet very seldom, even when there is an external 
demand (Interviewee 3)
 Could we have prepared all the guidelines? Yes, but, 
for that, we’d have to have more time, more avail-
ability (Interviewee 8).
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Membership requirements ignored the minimum 
criteria regarding members’ theoretical knowledge of 
medicine selection or experience in evidence-based 
evaluation:
 I got into this committee out of the blue (Interviewee 
8).
 I became a member and, you know, it’s not neces-
sarily because you fit the profile. There is no one 
else, so you have to go, to ensure the representation 
(Interviewee 9).
Further difficulties regarded unjustified member 
absenteeism and vacations taken by individual members 
or by a majority of the group at the same time. At hospital 
C, documents sent to the hospital management by the 
DTC president, transmitted the previous year, brought 
complaints to light regarding the lack of members’ 
participation in meetings.
In the rules or statutes of the DTCs of hospitals A, 
B and C, the collaboration of specialists and researchers, 
both internal and external (ad hoc), was not foreseen. 
In none of the hospitals was the use of strategies for 
controlling possible conflicts of interest regarding 
medicines mentioned by any of the interviewees.
Only hospital A appeared to perform most of the 
functions foreseen for the DTC (Table IV). In hospital 
C, medicines use policies that had been developed in the 
past were not followed. In hospitals B and D, definitions 
of therapeutic protocols and guidelines and of medicines 
use policies had not been established.
None of the DTCs aided the health care staff 
regarding information on medicines.
Criteria and methods used in medicine selection
The inclusion of medicines in the EML was limited 
to discussions, with little depth regarding the arguments 
presented by the applicant. In hospitals A and B, selection 
criteria were, at least, mentioned in the DTC statutes. 
One of the DTC members in hospital B reinforced the 
feeling that the implementation of selection criteria in the 
institution was conducted only superficially.
 We do as follows: we have a list of medicines. If the 
patient has a disease and the drug for it is listed, we 
accept the patient. If we don’t have the drug, we say 
that the drug of choice is not in the hospital´s EML 
[and turn the patient away], see? (Interviewee 11).
No methods were observed for comparisons of 
benefits and risks between the medicines suggested for 
inclusion in the EML and those already on the list. The 
only pre-existing condition for the request to be accepted 
for analysis was that it be accompanied by some type of 
literature:
 (...) at the moment when an application for inclu-
sion shows up, if it is accompanied by literature, the 
tendency is to approve [it](...) This new drug, due to 
the cost, may not be available at all times, but we do 
include it (Interviewee 8).
In hospital A, the evaluation of inclusion requests by 
the DTC would occur only after an evaluation feedback 
made by one of its members. However, the reviewer´s 
evaluation was always accepted without any debate by the 
other members. The requests submitted by DTC members 
were not passed on to reviewers. The medicine´s inclusion 
in the EML was automatic and became official at the 
following meeting.
In hospital B, neither analysis of inclusion requests 
by members nor a standardized review form were planned 
as minimum requirements in the evaluation process.
 (...) when we are analyzing a scientific paper, we must 
have someone to draft the main results and show it 
to us. (...) the members don’t have time for that (…) 
it ends up as a task of the applicant, and he (or she) 
will give you the information (Interviewee 11).
The analysis of evidence never included the 
investigation of the quality of evidence (i.e., sample size 
and methodology, internal validity) or external validity 
of the studies. One of the interviewees noted that these 
analyses would not be feasible in Brazilian hospitals:
 This is all very nice, but it’s not for us, OK? It’s not 
for Brazil. No one in this country can manage what 
the WHO recommends. (Interviewee 12)
The lack of organization and method in the evaluation 
process result in the insecurity of members when they are 
confronted with the need to make a selection decision:
 I can tell you there is no script, no dynamics for 
the evaluation (...) I felt unprepared for positioning 
myself strongly (Interviewee 13).
In hospitals C and D, medicine selection was based 
on written demands for the purchase of certain drugs, 
either as prescriptions or signed requests sent to the 
Pharmacy Service:
 The doctor makes a written request for the purchase 
of a non-standard medication. But if they begin ask-
ing for too much of the same medication, I decide to 
include it in the list (...) I don’t have time to research 
anything. [What I do is] I look at the price. If it’s 
The medicine selection process in four large university hospitals in Brazil: Does the DTC have a role? 179
expensive, I don’t decide it on my own, I send the 
request to my boss (Interviewee 17).
DISCUSSION
The selection of essential medicines represents 
one of the most important institutional policies for the 
rational use of medicines in health services (WHO, 
2002). Observed together, other pharmaceutical services 
– forecasting, procurement, stockage, distribution, drug 
utilization (prescribing, dispensing and use) – are based 
on the list produced by the selection process. The critical, 
independent, comparative and transparent evaluation of 
the available options must precede decision-making. The 
process reaches its goal with the selection of efficient, safe 
technologies for the profile of the population under care 
(Gustafsson et al., 2011). However, meeting these criteria 
demands the structuring of DTCs that are aware of and 
committed to this crucial activity.
In the four large university hospitals that were 
studied, several common barriers were found: (i) very 
poor structural conditions and limited resources for 
the work of the DTC, (ii) nonexistence of participation 
criteria for the DTC members, (iii) very limited 
availability of the members for DTC functions and lack 
of regular attendance at meetings, (iv) little knowledge or 
understanding by DTC members about their functions in 
the evaluation process, (v) lack of expertise by members 
for performing all DTC functions and (vi) superficial 
monitoring of the DTC activities by the hospital 
managements.
Recent studies (Marinho, 2003; Azevedo, Fernandes, 
Carreteiro, 2007; Bittencourt, Hortale, 2007) have 
highlighted grave problems related to the management, 
quality and efficiency of the care of patients hospitalized 
in the state of Rio de Janeiro. The precarious structures of 
the hospital DTCs indicate that the context in these large 
complex-care hospitals is very similar but certainly more 
serious given their nature as centers for specialized care.
The actual conditions of the medicine selection 
process in all four hospitals, made clear by the statements 
of the stakeholders, reinforce the dire situation of the 
DTCs in these university hospitals, mainly because the 
minimum requirements for DTCs have been discussed 
throughout the world for more than 30 years (Lima et 
al., 2010). One of the first documents on the selection 
of medicines in Brazil was developed by the Ministry of 
Education, under which university hospitals are organized. 
This 1986 document discussed the implementation of 
DTCs in university hospitals. This fact is paradoxical and 
worrisome: in 27 years, highly complex care evolved, 
intense adoption of health technologies occurred, but little 
has changed in these hospitals.
The decadent infrastructure of Brazilian university 
hospitals is one of the most acute expressions of the 
crisis these institutions have experienced over the years 
(Guimarães, 2004). Discussing the bases for a national 
health, science and technology and innovation policy, 
TABLE IV - Functions related to medicine selection in university hospitals. State of Rio de Janeiro, 2011
DTC ROLES AND 
RESPONSIBILITIES
HOSPITALS
A B C D
Assessment and 
selection of medicines  No monthly regularity. Poor evaluation.
Monthly meetings. 
Poor evaluation.
Suspended during the 
period of this study. Not done
Drafting of list as final 
product of medicine 
selection Yes Yes Not done Not done
Developing drug use 
policies
Only defined for anti-
infectives or for special 
unlisted under-protocol 
medicines
Not done Defined but not followed. Not done
Developing and 
monitoring therapeutic 
guidelines 
Related to the use of 
anti-infectives by the 
HIC.
Not done Not done Not done
Dissemination of 
information on medicines 
to hospital clinical board
Not done Not done Not done Not done
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Guimarães (2004) mentions the asymmetry between health 
benefits and costs and the speed at which health knowledge 
produced for the benefit of the population is appropriated. 
Another aspect of this crisis is the decrease in working 
hours of the best professionals in the hospital. This issue 
relates to DTC membership in the hospitals. Meeting 
attendance by members must be a requirement for the 
renewal of the member mandate in the DTC (WHO, 2003).
Stakeholders’ perceptions regarding their role in the 
DTC indicates insufficient knowledge about committee 
functions. Without organized planning and monitoring of 
the selection process of new therapeutic options, absolute 
inertia by managers may be observed, and rational drug 
use is abandoned altogether.
A study on individual lawsuits demanding medicines 
in the State of Rio de Janeiro observed that in 2006, 22% of 
the Brazilian Health System (SUS) medical prescriptions 
present in lawsuits originated in university hospitals 
(Sant’ana et al., 2011). This access strategy may be justified 
if needed medicines are not available in the system or if 
there has been tardiness in adoption. Nevertheless, health 
litigation may also promote the unwise or hasty adoption of 
new technologies of doubtful efficacy or untoward harmful 
effects of those without an established safety profile. This 
scenario allows for greater expenses and ineffectiveness 
of health care while making institutions more prone to the 
pharmaceutical industry´s marketing interests (Chieffi, 
Barata, 2010). As the results of this study showed, many 
stakeholders do not have the necessary skills to counter 
industry influence or the will to participate more fully in 
DTC functions, which could help prepare them for an 
adequate selection process. Moreover, no conflict of interest 
policies were observed for these committees, making 
members easy targets for undue influences.
During the analysis, we observed that the DTCs 
showed a vicious cycle of implementation. As hospital 
management teams changed over the years, all institutional 
policies regarding the use of medicines were constantly 
rebuilt and lost repeatedly. Some memory of past 
achievements existed in two hospitals, linked to members 
from the pharmacy services, but there had been no critical 
appraisal of these achievements.
The interviewees mentioned efficacy, safety and 
cost as criteria for selection. Comparative, user profile-
sensitive, needs- and evidence-based evaluation of 
medicines should have been the basis for the selection 
process (WHO, 2003). However, we observed that the 
DTC members were, in fact, exempting themselves from 
an in-depth analysis of the selection criteria, favoring, 
instead, political relations in the hospital as a ‘substitute’ 
criterion. The power behind the decision-making process 
on the adoption of health technologies in hospitals has 
been referred to in the literature, and university hospitals 
are the sites at which power struggles are prone to have 
consequences that may reflect on the health system as a 
whole (Cecilio, 1999; Medici 2001).
Even if the ‘power-based’ decision-making process 
was not primarily sensitive to need, it was very sensitive 
to the cost of the drugs to be included in the EML. This 
awareness was observed in two hospitals (B and D). In 
both cases, however, special efforts to counter a possible 
‘no inclusion’ decision were made by the manufacturers 
to empower the inclusion request. Interviewees mentioned 
these events. They were meant to convince larger numbers 
of health professionals within the institution and make 
way for the use and, lastly, inclusion of the drugs. This 
strategy is commonly used by the pharmaceutical industry 
(Angell, 2007).
The inability to manage effectively high-cost 
technologies in large institutions is similar to other cases 
studied in Brazil (Scheffer, 2008; Sancho, Vargens, 2009). 
Gertner (2010) followed up on the economic analyses 
performed by a company working for the pharmaceutical 
industry, showing that artificial demand was built for a 
new technology within the system, thus creating a market 
where there was none before. This situation is very distant 
from health priorities.
The Brazilian Network for Health Technology 
Assessment (HTA) – Rebrats5 – seeks to stimulate HTA 
hubs in teaching hospitals, introducing the HTA culture 
and training human resources for the activity (Brasil, 
2000, 2010; Getner, 2010 – include reference). During the 
selection process, DTCs should follow all important HTA 
criteria. However, the results from the DTCs in hospitals 
A, B, C and D show their inability to act as influential 
groups to prioritize and promote the discussion of HTA.
CONCLUSIONS
To deny the importance of DTCs for the Brazilian 
Health System is to disregard the fact that a cautious 
decision-making process is vital for efficacious, safe and 
cost-effective health care.
The interpretation of information obtained from 
in-depth interviews, the analysis of documents and 
direct observation techniques in four large complex 
university hospitals in Rio de Janeiro suggests that, even 
in those institutions that presented an operational DTC, 
the selection of medicines was inadequately performed. 
The results are most likely a consequence of a lack of 
organizational structure and of weak training of the 
members for the tasks involved.
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Efficacy, safety and cost were the principal criteria 
mentioned by the stakeholders involved in the process of 
medicines adoption in the hospitals. However, the analysis 
and interpretation of the results of this study indicate 
that decision-making is not, in fact, evidence-based and 
does not follow the above-mentioned criteria. Aspects 
such as the position or status of the health professional 
requesting inclusion of the medicine in the EML and 
industry influences may be contributing to the adoption of 
medicines. Moreover, the actual need for the technology 
appears to be viewed as less important.
University hospitals house an important array of 
new or highly complex technologies for SUS. This study 
contributed to the provision of relevant information about 
medicine selection in the state of Rio de Janeiro, especially 
of the process taking place in important teaching hospitals, 
which are trend-setters for the health system. While the 
results cannot be directly applied to other hospitals, we 
suggest that similar difficulties and barriers can be found 
in other facilities in the country.
Therefore, the selection process for new medicines 
performed in these hospitals must be carefully verified, 
and the flaws must be corrected. In the absence of the 
essential requirements for medicine selection long pointed 
out by the WHO, the first of which is the role of the DTC, 
the health system will remain hostage to the non-critical 
adoption of health technologies, strengthening the undue 
influence of the pharmaceutical industry, increasing health 
costs and producing risks for patients.
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